eVoucherRx lowers patients' financial responsibility for their diabetes therapy, positively influencing compliance and persistency; electronic coupon program works in real time at point of dispensing ACCU-CHEK(R) test strips.
INDIANAPOLIS, April 24 /PRNewswire/ -- Roche announced today the launch of its new eVoucherRx(TM) pilot program in California, designed to make it easier for patients with diabetes to receive their co-pay savings on ACCU-CHEK test strips. The program, active now at participating pharmacies, ensures patients with diabetes that their co-pay for ACCU-CHEK(R) test strips will not exceed $25. The program provides a discount of up to $40 per month, potentially lowering a patient's cost of blood glucose monitoring supplies by up to $480 per year.
eVoucherRx is a program that works in real time at the point of dispensing, which means patients do not need to do anything other than go to a participating pharmacy. To find a list of participating pharmacies, patients are encouraged to go online and visit www.accu-chek.com/evoucher.
"Lowering the patient's financial responsibility for diabetes therapy positively influences adherence and persistency in the self-management of their disease, especially during these challenging economic times," said Roche Vice President of Marketing Dan Kane. "eVoucherRx also helps prescribing physicians know that more of their patients will be able to afford their diabetes supplies. Our program that means less cost to our patients, it's seamless and hassle-free and it should lead to better health outcomes."
The eVoucherRx program is administered by RelayHealth for patients with commercial third-party health insurance. The program is not open to patients age 65 or older, cash-paying customers, patients on Medicare, Medicaid or those subsidized by other government-funded plans.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management--from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.
For more information, please visit accu-chek.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact: Julie Vincent Public Relations Manager ACCU-CHEK(R) Brand email@example.com 317-521-1910
Copyright©2009 PR Newswire.
All rights reserved